文献速递角膜与眼表疾病

培养角膜内皮细胞注射治疗角膜内皮失败的11例患者五年随访

Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure.
PubMed 文献 · Ophthalmology · 2020-09-06

这项前瞻性观察研究报道了首个人体临床试验组中11例假晶状体性角膜内皮失败患者接受培养人角膜内皮细胞(hCEC)注射治疗后的5年术后临床数据。5年时11眼中有10眼角膜内皮功能恢复正常,平均中央角膜内皮细胞密度为1257±467 cells/mm2,10只治疗眼最佳矫正视力显著改善,未观察到与hCEC注射治疗直接相关的主要不良反应。

要点

  • 5年时11眼中有10眼角膜内皮功能恢复正常。
  • 平均中央角膜内皮细胞密度为1257±467 cells/mm2(范围601-2067 cells/mm2)。
  • 10只治疗眼最佳矫正视力显著改善,平均视力从术前0.876 logMAR变为术后0.046 logMAR。

核心结论

  • 培养hCEC注射疗法在术后长达5年内安全有效。

研究设计与样本

  • 前瞻性观察研究,纳入2013年12月至2014年12月期间接受hCEC注射治疗的11例假晶状体性角膜内皮失败患者的11只眼。

主要发现

  • 术后5年,11眼中有10眼角膜内皮功能恢复正常。
  • 术后5年平均中央角膜内皮细胞密度为1257±467 cells/mm2(范围601-2067 cells/mm2)。
  • 10只治疗眼最佳矫正视力显著改善,平均视力从术前0.876 logMAR变为术后0.046 logMAR。
  • 未观察到与hCEC注射治疗直接相关的主要不良反应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To report the safety and efficacy of a novel cell injection therapy using cultured human corneal endothelial cells (hCECs) for endothelial failure conditions via the report of the long-term 5-year postoperative clinical data from a first-in-humans clinical trial group. DESIGN: Prospective observational study. PARTICIPANTS: This study involved 11 eyes of 11 patients with pseudophakic endothelial failure conditions who underwent hCEC injection therapy between December 2013 and December 2014. METHODS: All patients underwent follow-up examinations at 1 week, 4 weeks, 12 weeks, and 24 weeks and 1 year, 2 years, 3 years, 4 years, and 5 years after surgery. Specific corneal endothelial cell parameters (i.e., corneal endothelial cell density [ECD], coefficient of variation of area, and percentage of hexagonal cells) and central corneal thickness, best-corrected visual acuity (BCVA) on a Landolt C eye chart, and intraocular pressure (IOP) were recorded. MAIN OUTCOME MEASURES: The primary outcome was the change in central ECD after cell injection therapy, and the secondary outcome was corneal thickness, BCVA, and IOP during the 5-year-postoperative follow-up period. RESULTS: At 5 years after surgery, normal corneal endothelial function was restored in 10 of the 11 eyes, the mean ± standard deviation central corneal ECD was 1257 ± 467 cells/mm2 (range, 601-2067 cells/mm2), BCVA improved significantly in 10 treated eyes, the mean visual acuity changed from 0.876 logarithm of the minimum angle of resolution before surgery to 0.046 logarithm of the minimum angle of resolution after surgery, and no major adverse reactions directly related to the hCEC injection therapy were observed. CONCLUSIONS: The findings in this study confirmed the safety and efficacy of cultured hCEC injection therapy for up to 5 years after surgery.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Numa K, Imai K, Ueno M, et al. Five-Year Follow-up of First 11 Patients Undergoing Injection of Cultured Corneal Endothelial Cells for Corneal Endothelial Failure. Ophthalmology. 2020. PMID: 32898516. doi:10.1016/j.ophtha.2020.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。